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Cyclic adenosine monophosphate response-
element binding protein activation by mitogen-
activated protein kinase-activated protein kinase 3
and four-and-a-half LIM domains 5 plays a key
role for vein graft intimal hyperplasia
Keisuke Nakanishi, MD, Yukihiro Saito, MD, PhD, Nobuyoshi Azuma, MD, PhD, and
Tadahiro Sasajima, MD, PhD, Hokkaido, Japan
Objective: Intimal hyperplasia (IH) is the main cause of vein graft stenosis or failure after bypass surgery. Basic investigations
are proceeding in an animalmodel ofmechanically desquamated arteries, and numerousmolecules for potential IH treatments
have been identified; however, neither insights into the mechanism of IH nor substantially effective treatments for its
suppression have been developed. The goals of the present study are to use human vein graft samples to identify therapeutic
target genes that control IH and to investigate the therapeutic efficacy of these candidate molecules in animal models.
Methods:Using microarray analysis of human vein graft samples, we identified two previously unrecognized IH-related genes,
mitogen-activated protein kinase–activated protein kinase 3 (MAPKAPK3) and four-and-a-half LIM domains 5 (FHL5).
Results: Transfer of either candidate gene resulted in significantly elevated vascular smooth muscle cell (VSMC)
proliferation and migration. Interestingly, cotransfection of both genes increased VSMC proliferation in an additive
manner. These genes activated cyclic adenosine monophosphate response-element (CRE) binding protein (CREB), but
their mechanisms of activation were different. MAPKAPK3 phosphorylated CREB, but FHL5 bound directly to CREB.
A CREB dominant-negative protein, KCREB, which blocks its ability to bind CRE, repressed VSMC proliferation and
migration. In a wire-injurymousemodel, gene transfer of KCREB plasmid significantly repressed IH. In this vessel tissue,
CRE-activated gene expression was repressed. Furthermore, we confirmed the changes in MAPKAPK3 and FHL5
expression using vein graft samples from eight patients.
Conclusions:We successively identified two previously unrecognized IH activators, MAPKAPK3 and FHL5, using human
vein graft samples. Gene transfer of KCREB repressed IH in an animal model. Inhibition of CREB function is a
promising gene therapy strategy for IH. (J Vasc Surg 2013;57:182-93.)
Clinical Relevance: Intimal hyperplasia (IH) is the cause of vein graft stenosis or failure after bypass surgery. However,
no therapeutic targets for the treatment of IH have been identified. We identified two previously unrecognized
IH-inducing molecules, mitogen-activated protein kinase–activated protein kinase 3 (MAPKAPK3) and four-and-a-half
LIM domains 5 (FHL5), using gene expression profiling of human vein graft samples and demonstrated that
MAPKAPK3 and FHL5 can activate cyclic adenosine monophosphate response-element binding protein (CREB) and a
promising strategy for treating IH via gene transfer of KREB, a dominant-negative variant. Our study began with one
patient, and we confirmed our findings on MAPKAPK3 and FHL5 expression using vein samples from eight other
patients. We believe that these results will lead to new clinical approaches to IH.
s
a
i
d
c
t
o
I
i
i
a
g
l
sFrom the Department of Surgery, Asahikawa Medical University.
This work was supported by a Grant-in-Aid from the Ministry of Education,
Culture, Sports, Science and Technology of the Japanese Government.
Author conflict of interest: none.
Additional material for this article may be found online at www.jvascsurg.org.
Reprint requests: Tadahiro Sasajima, MD, Professor and Chairman, Depart-
ment of Surgery, Asahikawa Medical University, 2-1 Midorigaoka-Higashi,
Asahikawa, Hokkaido 078-8510, Japan (e-mail: sasajima@asahikawa-med.
ac.jp).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a conflict of interest.
0741-5214/$36.00
Copyright © 2013 by the Society for Vascular Surgery.
http://dx.doi.org/10.1016/j.jvs.2012.06.082
182Vein graft is the choice of conduit for arterial bypass
urgery. However, the prevalent patency rate of vein grafts
t 5 years after bypass surgery is 70%, regardless of the
mplantation procedures used to treat peripheral arterial
isease (PAD)1,2 or coronary artery disease.3 The main
ause of vein graft failure is intimal hyperplasia (IH), and
wo types of IH occur clinically: nonprogressive IH, which
ccurs in arterialized vein graft segments, and progressive
H, which leads to stenotic lesions. Nonprogressive IH is
nitiated with endothelial denudation immediately after
mplantation but commonly ceases within several weeks
fter completion of re-endothelialization. Conversely, pro-
ressive IH results in graft stenosis,4,5 which is commonly
ocalized and segmental; the most common site of progres-
ive IH is in a venous valve, and progressive IH occurs in
15% of vein grafts after implantation.6,7 Furthermore,
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Volume 57, Number 1 Nakanishi et al 183according to the Project of Ex-Vivo vein graft Engineering
via Transfection III (PREVENT III) trial data that were
more contemporary and highly vetted, the occurrence of
nontechnical graft failure resulting in graft revision or ma-
jor amputation within 12 months of enrollment is 25.5%.8
Although many factors, including inflammation, endo-
thelial dysfunction, and alterations in remodeling and
matrix deposition contribute to the mechanisms of IH,
we believe that the most important factors leading to IH
of a vein graft are changes in the phenotype of the tunica
media smooth muscle cells in the endothelial denudation
area and their migration and proliferation. IH involves
the extracellular matrix and the vascular smooth muscle
cells (VSMCs) that proliferate and migrate from the
tunica media, and the progression of IH contributes to
the development of stenotic lesions.8-10 VSMCs change
their phenotype from a quiescent contractile state to a
synthetic motile state and migrate from the medial layer
into the intimal layer11-13; synthetic-state VSMCs rap-
idly proliferate and contribute to IH.
Simultaneously, vascular injury itself induces acceler-
ated apoptosis in the intimal layer.14,15 Therefore, numer-
ous extracellular stimuli and intracellular signal transduc-
tion cascades are involved in these complex mitogenic,
synthetic, and apoptotic processes. To better understand
and develop preventative therapies for progressive IH with
its complex pathology, basic investigations using an animal
model of mechanically desquamated arteries are underway.
Indeed, numerous experimental molecules for potential IH
treatments have reportedly been successfully used as treat-
ments in animal models of IH; however, neither insights
into the mechanism of IH nor successful treatments for its
suppression have been developed.
For example, ex vivo gene therapy with an E2F decoy
oligodeoxynucleotide had a significant inhibitive effect on
vein graft IH in animal models.9 However, although early
results from a single-center, randomized, controlled trial
were promising, the E2F decoy therapy failed to demon-
strate any significant affect on vein graft failure after coro-
nary and peripheral artery bypasses in late-phase clinical
trials.8,11 Within this framework, we analyzed failing vein
grafts in humans to identify new targets for IH treatment.
Stenosis and arterialized segments due to IH were exam-
ined. Here, we identify the potential therapeutic target
genes that can control IH and are indispensable for the
investigation of the therapeutic efficacy of the candidate
molecules in animal models.
METHODS
We obtained approval from the Institutional Review
Board of Asahikawa Medical University and written in-
formed consent from all patients.
Human vein graft samples for complementary
DNA microarray analysis. Vein graft samples were col-
lected from a 72-year-old man with PAD during a revision
operation. The patient had previously undergone periph-
eral arterial bypass grafting (sample 0, Supplementary Table
I, online only). The intimal hyperplasia lesion was a mono- iocal, midgraft stenosis. The following samples were col-
ected: sample 1, normal pregrafted vein as control; sample
, normal postgrafted vein as normal graft; and sample 3,
tenotic postgrafted vein as stenotic graft. “Normal pre-
rafted vein” refers to a part of the arm vein used to replace
he lesion area in the revision operation, and “normal
ostgrafted vein” refers to a graft of a healthy area slightly
part from the stenosis lesion but still part of the same graft.
The samples were divided for whole-vessel analysis and
unica media analysis. The tunica media samples were ex-
racted from vessel wall using laser capture microdissection
Supplementary Fig 1, online only). Affymetrix Genechip
nalysis (Gene Chip probe array; Human Genome U133
lus2 Array, Santa Clara, Calif) was performed using com-
limentary (c)DNA generated from these samples.We used
hree protocols for the gene chip analysis: WT-Ovation
ico RNA Amplification System (NuGEN Technologies
nc, San Carlos, Calif), FL-Ovation cDNA Biotin Module
2 (NuGEN Technologies, Inc), and Affymetrix Ge-
eChip Expression Analysis. The instruments and analysis
oftware used for the gene chip analysis are listed in Sup-
lementary Table II (online only).
Human vein graft for reverse transcription-
olymerase chain reaction and immunofluorescence
nalysis. Additional vein graft samples from eight other
atients with PADwere analyzed to assess expression of the
andidate genes identified in the chip array analysis (Sup-
lementary Table II, online only).
Cell culture. The VSMCs were normal human aortic
mooth muscle cells purchased from Lonza Walkersville
nc (Walkersville, Md) and maintained in smooth muscle
rowth medium (Lonza) supplemented with 10% fetal
ovine serum (FBS) and smooth muscle growth supple-
ent (including recombinant human endothelial growth
actor, insulin, GA-1000, human fibroblastic growth fac-
or, and bovine serum albumin). BHK-21 cells were main-
ained in Dulbecco’s modified Eagle medium containing
0% FBS, 100 U/mL penicillin, and 100 mg/mL strepto-
ycin. All cultures were incubated at 37°C in a humidified
tmosphere of 95% air and 5% CO2; medium was ex-
hanged every 2 days. All cells were used at passages five to
ight for subsequent experiments. The cells were trans-
ected with Lipotrust EX gene reagent (Hokkaido System
cience Co Ltd, Hokkaido, Japan).
Mouse wire-injury model and gene transfer protocol.
ll animal protocols were approved by the Animal Ethics
ommittee of Asahikawa Medical College. Wild-type male
57BL/6J mice (11 weeks old) were anesthetized with
.5% to 2.5% isoflurane in a mixture with air. Surgery was
arried out as described previously.16 The left femoral
rtery was exposed by blunt dissection. The accompanying
emoral nerve was carefully separated, but the femoral vein
as not isolated from the artery. The femoral artery and
ein were temporarily ligated at proximal and distal sites
ith a 6-0 silk suture for temporary vascular control during
he procedure. A small branch of the femoral artery be-
ween the rectus femoris and vastus medialis muscles was
solated, temporarily ligated proximally, and ligated distally
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January 2013184 Nakanishi et alwith 6-0 silk sutures. Veins and connective tissues around
the artery were carefully removed. The exposed muscular
branch artery was dilated by topical application of one drop
of 1% lidocaine hydrochloride. Transverse arteriotomy was
performed in the muscular branch.
Next, a straight spring wire (0.38 mm in diameter,
Cook, Bloomington, Ind) was carefully inserted into the
femoral artery toward the iliac artery for a distance5 mm.
The wire was left in place for 1 minute to denude and dilate
the artery. The wire was removed. The injured segment was
transiently isolated by temporary ligatures.
Plasmids were transfected using the microbubble-
enhanced ultrasound method.17,18 A cyclic adenosine
monophosphate (cAMP) response-element (CRE) bind-
ing protein (CREB) dominant-negative (KCREB) plasmid
or green fluorescent protein (GFP) plasmid (20 g) with
20 L of 20% Levovist (Bayer AG, Leverkusen, Germany)
solution was incubated within the lumen, which was ex-
posed to ultrasound for 10 seconds (2.5 W/cm2). Each
femoral artery was collected 5 days after injury for gene ex-
pression analysis or 3 weeks after injury for histopathologic
analysis. For histopathologic analysis, cross-sections were
stained with elastica van Gieson and elastica Masson
trichrome, using the protocols described in the Supplemen-
tary Methods (online only). Morphometric analysis was per-
formed using ImageJ software (National Institutes of Health,
Bethesda, Md).
Other materials and methods used in this study are
described in the Supplementary Methods (online only),
including the instruments and analysis software that were
used for the gene chip analysis, cell proliferation assay, cell
migration, immunofluorescence analysis, Western blotting,
luciferase reporter gene assay, gel mobility shift analysis,
and competition and antibody analysis, polymerase chain
reaction, protocols for elastica van Gieson staining, proto-
cols for elastica Masson’s trichrome staining, and plasmid
constructs.
Statistical analysis. All results are expressed as mean
standard error of the mean. Statistical analysis was performed
using StatView 5.0 software (SAS Institute, Inc, Cary,
NC). Data were compared using the unpaired Student
t-test for comparisons between two groups, using anal-
ysis of variance, followed by the Dunnett test for pairwise
comparisons against the control and the Tukey test for
multiple comparisons. Differences were considered sig-
nificant at P  .05.
RESULTS
First screening for candidate intimal hyperplasia-
related genes. Human cDNA samples were screened us-
ing Affymetrix Genechip analysis to identify genes that may
be involved in IH. A scatterplot revealed that gene expres-
sion was highly variable in whole-vessel samples with IH
(Fig 1, A; left panel). Data from tunica media samples were
more scattered than those from whole-vessel samples (Fig
1, B; right panel). A hierarchic cluster analysis revealed that
the gene expression pattern of each type of sample was Mnique; the pattern of gene expression in stenotic veins was
articularly distinct (Fig 1, B).
Functional screening for candidate genes. We fo-
used on the 13 genes that were most highly upregulated in
he stenotic area. These genes showed at least a twofold
hange or a high level of lesion-specific expression accord-
ng to the cluster analysis. Eight of the 13 candidate genes
ere selected from the whole-vessel analysis, and seven
ere selected from the tunica media samples. All compari-
ons were between normal and stenotic vein grafts. Func-
ional screening was performed in VSMCs and BHK-21
ells. Proliferation was assessed using the c-fos promoter
ssay (Fig 1, C; vascular smooth muscle cell (VSMC), and
upplementary Fig 2, B, online only; BHK-21) and the
-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
-(4-sulfophenyl)-2H-tetrazolium assay (Supplementary Fig
,A; VSMC, and 2,C; BHK-21, online only). Cell migration
as assessed using amodifiedBoyden-chamber assay (Supple-
entary Fig 2,D, online only; VSMC).We used these data to
elect genes 2 and 9 for further analyses because they seemed
o encode IH activators.
Nucleotide sequencing revealed that the sequence
f gene 2 matched the sequence of the human mitogen-
ctivated protein kinase-activated protein kinase 3
MAPKAPK3) cDNA (GenBank accession number
M_004635.3), and the sequence of gene 9 matched
he sequence of the human four-and-a-half LIM do-
ains 5 (FHL5), transcript variant 1, cDNA (GenBank
ccession number NM_020482.4).
Function and mechanism of MAPKAPK3 and
HL5. VSMCs were cultured under four conditions: (1)
ormal conditions as a control; (2) hypoxia (1% oxygen);
3) with 250 mol/L H2O2; and (4) with 50 ng/mL
latelet-derived growth factor (PDGF) for 24 hours for
ach set of conditions. Candidate gene expression was
xamined using reverse transcription-polymerase chain re-
ction.MAPKAPK3messenger RNA (mRNA) was down-
egulated in H2O2-treated cells. FHL5mRNAwas upregu-
ated in hypoxic and PDGF-treated VSMCs (Fig 2, A).
To confirm the function of the candidate genes, cell
roliferation and cell migration were assessed in VSMCs
ransfected with each candidate gene alone or with both
andidate genes together. Notably, cotransfection of both
andidate genes resulted in significantly higher VSMC pro-
iferation than did transfection of MAPKAPK3 or FHL5
lone, and the effect of cotransfection on proliferation,
elative to that of single-gene transfection, was additive
P  .05; Fig 2, B and C).
We next focused on the mechanism of VSMC prolifer-
tion activation by MAPKAPK3 and FHL5. The results of
uciferase reporter assays showed many signaling pathways,
ncluding the cyclic AMP response element (CRE), serum
esponse element (SRE), activator protein 1 (AP-1), Myc,
nd nuclear factor (NF)-B pathways, were significantly
ctivated by overexpression of MAPKAPK3 or FHL5 com-
ared with the control (P  .05; Fig 2, D). However, the
2F pathway was activated only by FHL5 and not by
APKAPK3 (P  .05; Fig 2, D).
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Volume 57, Number 1 Nakanishi et al 185Fig 1. First screening for candidate intimal hyperplasia-related genes and functional screening for candidate thera-
peutic target genes. A, Scatterplot of data from whole-vessel and tunica-media samples at the period of intimal
hyperplasia (normal postgrafted vein vs stenotic postgrafted vein). B, Hierarchic cluster analysis for whole vessel and
tunica media for control vein (control); normal postgrafted vein (nondisease); and stenotic postgrafted vein (disease).C,
Effect of candidate gene plasmid on c-fos promoter activity in vascular smooth muscle cells. A plasmid encoding the
green fluorescent protein was transfected as a control. Negative control cells were incubated in medium containing 1%
fetal bovine serum. Positive control cells were incubated in medium containing 15% fetal bovine serum (n  8). *P 
.05 vs negative control. Genes 2 and 9 (arrows) were selected as two candidate genes. The range bars show the standard
error of the mean.
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ated with IH were upregulated by the transfection of the
candidate genes, a previous report demonstrated that
MAPKAPK3 and FHL5 can directly activate CREB,19 a
transcription factor that binds to CRE. We examined the
effect of MAPKAPK3 and FHL5 expression on CRE
activity in BHK-21 cells using a CRE-luciferase reporter.
Fig 2. Function and mechanism of mitogen-activated p
four-and-a-half LIM domains 5 (FHL5). A, Reverse-transc
endogenous candidate genes is shown under four condition
vascular smoothmuscle cell proliferation, as determined usin
2-(4-sulfophenyl)-2H-tetrazolium assay. A plasmid-encodi
(n  12). *P  .05 vs control. †P  .05 vs MAPKAPK3
vascular smooth muscle cell migration, as determined u
transfected as a control (n  6). *P  .05 vs control. D
transfection of a candidate gene into BHK-21, pathway in
plasmid was transfected as a control (n  8). *P  .05 vs
luciferase transcription in baby-hamster-kidney cell line
monophosphate response-element (CRE) motif, and tran
plasmid was transfected as a control (n  12). *P  .05 vs
protein 1;GAPDH, glyceraldehyde-3-phosphate dehydrog
factor; SER, serum response element. The range bars showOverexpression of MAPKAPK3, FHL5, or both, signif- acantly increased CRE activity to the level of the control
P  .05; Fig 2, E). Interestingly, combined overexpres-
ion of MAPKAPK3 and FHL5 resulted in significantly
igher CRE activity than overexpression of eitherMAPKAPK3
r FHL5 (P .05; Fig 2, E).
CREB activation by MAPKAPK3 and FHL5.
APKAPK3 phosphorylates serine 133 of CREB (CREB133),
n kinase-activated protein kinase 3 (MAPKAPK3) and
n polymerase chain reaction analysis of expression of two
Effect of a plasmid encoding a candidate gene is shown on
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
een fluorescent protein (GFP) was transfected as a control
HL5. C, Effect of plasmid encoding a candidate gene on
modified Boyden chamber assay. A GFP plasmid was
eening for the induction of key signaling pathways after
on was evaluated based on reporter gene activity. A GFP
rol. E, Effect of a plasmid encoding a candidate gene on
ciferase transcription was driven by a cyclic adenosine
ion was monitored using a reporter gene assay. A GFP
ol. †P  .05 vs MAPKAPK3 and FHL5. AP-1, Activator
NF-B, nuclear factor-B;PDGF, platelet-derived growth
tandard error of the mean.rotei
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Volume 57, Number 1 Nakanishi et al 187CREB was significantly phosphorylated (p) in the nuclei of
VSMCs that overexpressed FHL5 or MAPKAPK3 com-
pared with controls, but the amount of total CREB protein
was not altered (P  .05; Fig 3, A). Immunofluorescence
staining demonstrated that FHL5 tagged with hemagglu-
Fig 3. Cyclic adenosine monophosphate response-elem
protein kinase-activated protein kinase 3 (MAPKAPK3)
of a FHL5 plasmid or a MAPKAPK3 plasmid on phosp
Western blot. A plasmid encoding the green fluorescent p
control. B, Representative pictures of immunofluorescen
after candidate gene transfection. A GFP plasmid was tra
indicates nuclear staining (blue), p-CREB indicates stainin
staining with antihemagglutinin antibody (red). Images
plasmid encoding hemagglutinin-tagged FHL5 on CRE
mobility shift assay. D, Effect of overexpression of each
gene expression of cyclin A, Ras-related C3 botulinum t
assessed using quantitative real-time reverse-transcription
a control. n  8. *P  .05 vs control. The range bars shtinin was mainly overexpressed in nuclei and p-CREB was clso located in nuclei of VSMCs; in contrast, MAPKAPK3
as mainly overexpressed in the cytoplasm, and p-CREB
as located in the nuclei and cytoplasm of VSMCs (Fig 3,
). These results indicated thatMAPKAPK3 could increase
-CREB in the nucleus and cytoplasm, whereas FHL5
inding protein (CREB) activation by mitogen-activated
r-and-a-half LIM domains 5 (FHL5), or both.A, Effect
ation of the serine residue of CREB, as determined by
n (GFP) was transfected as a control. n 3. *P .05 vs
ning of vascular smooth muscle cells (VSMC) 48 hours
ed as a control. DAPI (4’,6-diamidino-2-phenylindole)
h anti-p-CREB (Ser133) antibody (green),HA indicates
hown at original magnification 1000. C, Effect of a
A biding activity, as determined by an electrophoretic
date gene on vascular smooth muscle cell CREB target
substrate 1 (Rac-1), and B-cell lymphoma 2 (Bcl 2), as
merase chain reaction. A GFP plasmid was transfected as
e standard error of the mean.ent b
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horyl
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January 2013188 Nakanishi et alappears to transport p-CREB to the nucleus. Gel mobility
shift assays demonstrated that overexpression of FHL5
resulted in increased CREB-DNA binding activity and
supershifted with anti-FHL5, CREB, and hemagglutinin
antibodies (Fig 3, C). These results indicated that FHL5
could form a complex with CREB and that this complex
could bind to CREDNA sequence in VSMCs (Supplemen-
tary Fig 3, online only).
There are CRE sites in the promoters of cyclin A, Ras-
related C3 botulinum toxin substrate 1 (Rac-1), and B-cell
lymphoma 2 (Bcl 2).22,23,24 In fact, relative to the overexpres-
sion of the GFP control, overexpression of MAPKAPK3,
FHL5, or both resulted in significant upregulation of the
expression of these genes (P  .05; Fig 3, D).
Inhibition of MAPKAPK3 and FHL5-induced ac-
tivation by dominant-negative CREB. Based on our in
vitro data and previous reports,24,25 we assessed the hy-
pothesis that dominant-negative CREB would repress IH.
To test this concept, two plasmids encoding different dom-
inant-negative CREB mutants were used. The CREB133
plasmid encoded a mutant variant that replaces serine 133
with an alanine; this mutation prevented phosphorylation
of CREB. The KCREB plasmid encoded a mutant variant
that containedmutations in the CRE-binding domain. The
effect of the CREB133 or KCREB plasmid on the phos-
phorylation of the serine residue of CREB was confirmed
by Western blotting (Supplementary Fig 4, online only).
To assess the difference between the effects of two types
of KCREB on CRE activity in BHK-21 cells, CRE-
luciferase reporter gene assays were performed. Relative to
the GFP control, KCREB significantly repressed both
MAPKAPK3-induced and FHL5-induced CRE activity,
but CREB133 only repressed MAPKAPK3-induced CRE
activity and did not repress FHL5-induced CRE activity
(P  .05; Fig 4, A). Furthermore, to confirm the effect of
KCREB on the molecular level, a gel mobility shift assay
was performed using nuclear extract proteins of VSMC that
were cotransfected with each candidate gene and KCREB.
KCREB completely prevented the formation of the FHL5-
CREB-CRE complex and inhibited the formation of the
MPAKAPK3-induced CREB-CRE complex (Fig 4, B).
These results indicated that CREB133 could only repress
the MAPKAPK3-induced activation of CREB and could
not inhibit the CREB-transport function of FHL5. Thus,
KCREB can repress the CREB activation induced by both
MAPKAPK3 and FHL5.
Transfer of KCREB, relative to transfer of the GFP
control, significantly repressed the proliferation and migra-
tion that was induced by MAPKAPK3 or FHL5 (P  .05;
Fig 4, C and D).
Gene therapy with KCREB in vivo. Given the in
vitro data, we sought to test the effects of KCREB on IH
in an animal model. An adenoviral vector encoding a
dominant-negative CREB suppressed IH in balloon-
injured rat carotid arteries.24,25 However, viral vectors have
several safety problems in clinical applications. We therefore
created a wire-injury mouse model, and the KCREB plasmid
was transfected into the injured artery using the ultrasound- ronoporation method.17,18 We confirmed that the trans-
ection efficiency of a GFP plasmid was high by using an
mmunofluorescence assay and a Western blot to assess ex-
ression (Supplementary Fig 5, online only). In the control
roup, expression of MAPKAPK3 and FHL5 mRNAs was
pregulated 1 week after injury but rapidly reverted to base-
ine levels (Fig 5, A). In contrast, the expression of CREB
RNA was not significantly upregulated (Supplementary Fig
, online only). Immunofluorescence staining of a mouse
emoral artery after wire injury demonstrated that MAP-
APK3 and FHL5 were expressed and localized to the
ntimal and medial areas (Supplementary Fig 7, online
nly).
Histopathologic analysis revealed that gene transfer of
he KCREB plasmid repressed IH, whereas intensive IHwas
bserved in the control group (Fig 5, B). Indeed, the intima-
o-media (I/M) ratio and the intimal area was significantly
ower in the KCREB group than in the GFP control group 3
eeks after injury (Fig 5, C and D). In addition, the lumen
rea, as a percentage of the total artery area was maintained in
he KCREB group (Supplementary Fig 8, A, online only).
bsolute values of histopathologic analysis are presented in
upplementary Fig 8, B (online only).
Levels of mRNA cyclin A and Bcl 2 were significantly
ower in the KCREB group than in the GFP group (P 
05; Fig 5, E), and the levels of c-fos and Rac1 were also
ower in the KCREB group than in the GFP group (not
ignificant; c-fos, P  .156; Rac 1, P  .470; Fig 5, E).
Expression of MAPKAPK3 and FHL5 in human
ein graft samples. Although we would have preferred to
se a small cohort study to select the candidate genes, we
ere required to initiate the microarray analysis screen
sing one patient due to the need to select patients with
inimal comorbidity and influence from medications.
herefore, we confirmed the expression of MAPKAPK3
nd FHL5 in additional human vein graft samples. Eight
atients with PAD who underwent revision or repeat
ypass grafting surgery at Asahikawa Medical University
rom March 2008 to April 2010 were enrolled. The
upplementary Table I (online only) details each pa-
ient’s background. In the stenotic vein grafts, expres-
ion of MAPKAPK3 was detected in seven patients. Further-
ore, strong expression of FHL5 was detected in stenotic
ein grafts of five patients, and weak expression was detected
n one patient (Fig 6, A). Immunofluorescence staining of
tenotic vein grafts demonstrated that MAPKAPK3 and
HL5 were expressed and localized to the medial area
Fig 6, B and C).
ISCUSSION
Here, we identified two previously unrecognized
H-inducing molecules, MAPKAPK3 and FHL5, and
emonstrated a strategy for treating IH based on analysis
f human vein graft samples. We found that MAPKAPK3
nd FHL5 both had the potential to activate CREB and
hat activated CREB could bind to CRE; these events
esulted in the induction of VSMC growth and IH.
t
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a mouse model of IH.
MAPKAPK3 encodes a member of the Ser/Thr pro-
tein kinase family. Extracellular signal-regulated kinase,
Fig 4. Inhibition of mitogen-activated protein kinase-acti
a-half LIM domains 5 (FHL5)-induced activation by cycli
(CREB) dominant-negative variants CREB133 andKCREB
a candidate gene on luciferase transcription in baby-hamst
CRE motif; effects were assessed using a reporter gene assa
transfected as a control. n10. *P .05 vs control. †P .0
gene and KCREB on CREB-DNA biding activity was asses
was transfected as a control.C, Effect of overexpression of a
vascular smooth muscle cell proliferation. A GFP plasm
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)
control. †P .05 vs candidate	GFP.D, Effect of overex
muscle cell migration. AGFP plasmid was transfected as a co
The range bars show the standard error of the mean.p38 MAP kinase, and c-Jun N-terminal kinase were all able ao phosphorylate and activate this kinase, which suggests
hat MAPKAPK3 has a role as an integrative element of
ignaling in both mitogen and stress responses.26-28 Acti-
ated MAPKAPK3 can phosphorylate Ser-133 of CREB
protein kinase 3 (MAPKAPK3)-induced or and four-and-
osine monophosphate response-element binding protein
ffect of overexpression of a dominant-negativeCREB and
ney cell line 21; luciferase transcription was driven by the
lasmid encoding the green fluorescent protein (GFP) was
andidate	GFP.B,Effect of overexpression of a candidate
ing an electrophoretic mobility shift assay. A GFP plasmid
idate gene and of dominant-negative CREB (KCREB) on
s transfected as a control; effects were assessed using a
sulfophenyl)-2H-tetrazolium assay. n  10. *P  .05 vs
n of a candidate gene and of KCREB on vascular smooth
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TNF-
–induced VSMCmigration and induces apoptosis
in VSMCs23. Transfer of CREB133 into balloon-
Fig 5. Gene therapy with a dominant-negative cyclic adeno
variant,KCREB, invivo.A,Expressionof thecandidategenesa
using quantitative real-time reverse-transcription polymer
MAPKAPK3, mitogen-activated protein kinase-activated prot
green fluorescent protein (GFP)- or KCREB-transfected arteri
weeks after vascular injury (bar200m).C, Intimal area-to-
area of lumen, intima, and media in injured arteries transfect
Boyden chamber assay. n 8. *P .05 vs GFP. E,CREB
or KCREB 5 days after wire injury. n 6. *P .05 vs GFinjured arteries of rats represses the progress of IH.24 towever, this approach has not been translated into
linical use.
FHL5 was identified as the first tissue-specific coactiva-
monophosphate response-element binding protein (CERB)
2,or3weeksaftermouse femoral arterywire injuryasassessed
hain reaction. FHL5, four-and-a-half LIM domains 5;
nase. n 6. *P .05 vs 0week.B,Representative images of
nedwith elastica vanGieson and elasticaMasson trichrome 3
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Volume 57, Number 1 Nakanishi et al 191LIM-only protein that associates with a cAMP response
elementmodulator (CREM) in the germ cells of malemice.
Classically, CREB-binding protein is necessary for CREB
activation and CREB-DNA binding. Instead, FHL5 acti-
vates CREB and CREM in a CREB-binding protein–
independent manner.20,29 Human FHL5 mRNA has not
been detected in the adult testis, and the FHL5 mRNA has
only been found in human tumor cell lines derived from
squamous cell carcinoma, melanoma, and leukemia.30 This
report is the first to demonstrate a relationship between
FHL5 and IH.
To confirm the function of the candidate genes, short
hairpin (sh)-RNA plasmids of MAPKAPK3 and FHL5
were created and transfected in vitro and in vivo study.
However, a significant result was not obtained by these
studies (Supplementary Figs 9 and 10, online only). Next,
Fig 6. Expression of mitogen-activated protein kinase-
and-a-half LIM domains 5 (FHL5) in human vein graft
samples as assessed using reverse-transcription polyme
phosphate dehydrogenase. B, C, Serial cross-sections of h
MAPKAPK3, FHL5, and 
-smooth muscle action (S
phenylindole (DAPI). I, Intimal area; M, medial area (owe found that MAPKAPK3 and FHL5 both had the po- mential to activate CREB and that MAPKAPK3 and FHL5
ach activated CREB via a distinct mechanism. Specifically,
APKAPK3 activated CREB by phosphorylation of the
er-133 site; in contrast, FHL5 activated CREB by a bind-
ng interaction and likely acted as a cofactor and contrib-
ted to transport of p-CREB.19 The result from our in vitro
tudy indicates that inhibition of the phosphorylation of the
er-133 site alone would not be insufficient to inhibit IH in
therapeutic strategy for IH; therefore, a more radical
trategy is required to repress CREB function. KCREB acts
s a dominant repressor by forming an inactive dimer with
REB and blocking its ability to bind CRE. Thus, we
ssessed the hypothesis that KCREB can repress CREB
unction induced by both MAPKAPK3 and FHL5. In fact,
ur results supported this hypothesis.
A stringent genome-wide analysis for CREB-binding
ted protein kinase 3 (MAPKAPK3)-induced and four-
les. A, Candidate gene expression in human vein graft
chain reaction. n  8. GAPDH, Glyceraldehyde-3-
n vein graft samples were stained with antibodies against
samples were counterstained with 4’,6-diamidino-2-
l magnification, 200).activa
samp
rase
uma
MA),otifs revealed 1349 such sites in the mouse genome and
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putative CREB-regulated genes and the extremely large
functional diversity of the proteins encoded by these genes
indicate that CREB has important roles in many cellular
processes, including IH. Here, pathway screening showed
that MAPKAPK3 and FHL5 each activated many path-
ways, including SRE, CRE, AP-1, myc, and nuclear factor-
B. CREB is activated by various activators, and CRE is
activated by activated CREB on many promoters. The
CRE-CREB complex is a pleiotropic activator that partici-
pates in the induction of a wide variety of cellular and viral
genes and clearly plays a key role in IH on vein grafts.
CREB activation by vascular toxins is a healthy re-
sponse that is intended to decrease oxidant injury and
inflammation and maintain VSMC survival and function.32
Cilostazol promotes VSMC differentiation through the
CREB signaling cascade.33 The explanation for these dif-
ferences from our finding that CREB affected VSMC phe-
notype remains unclear.34,35 These differences may be due
to the mechanism of CREB activation or the amount of
CREB expression in VSMCs. We hypothesize that the
effect of CREB on the VSMC phenotype changes depend-
ing on which molecule activates CREB rather than the
amount of CREB.
Asmentioned above, there are several reports about the
relation between CREB and vascular IH, and the role of
CREB in vessel wall remodeling remains controversial.
However, these were in vitro studies or studies in animal
models. In contrast, our study was started with samples
from a patient, and we confirmed these changes in MAP-
KAPK3 and FHL5 using vein graft samples from eight
other patients. Although the final results of our study are
similar to results in previous reports, the implications are
completely different.
CONCLUSIONS
We used human vein graft samples to successively
identify two previously unrecognized activators of IH,
MAPKAPK3 and FHL5. Gene transfer of KCREB, a
dominant-negative variant of CREB, repressed IH in a wire-
injury mouse model of vein denudation. We believe that the
results of the present study will lead to new therapeutic ap-
proaches for IH.
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Cell proliferation assay. Proliferation of vascular
smooth muscle cells (VSMCs) seeded in 24-well plates
was measured using the 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
assay 48 hours after transfection with plasmid vectors. Ap-
proximately 80 L of CellTiter 96 One Solution Reagent
(Promega,Madison,Wisc) in 400LofDulbecco’smodified
Eagle’s medium (DMEM) was added to each well, and the
absorbance of solution was measured at 490 nm.
A c-fos promoter assay was performed using VSMCs or
baby-hamster-kidney 21 cells by cotransfection with the
c-fos–luciferase reporter gene (p2FTL) and target gene. The
c-fos-luciferase reporter gene consisted of two copies of
the c-fos 5=-regulated enhancer element (357 to 276),
the herpes simplex virus thymidine kinase gene promoter
(200 to 70), and the luciferase gene. At 5 hours after
transfection, the transfected cells were incubated with 1%
fetal bovine serum (FBS)-containing medium for 24 hours.
The cells were washed with phosphate-buffered saline
(PBS) and lysed by being incubated in 100 L of cell lysis
buffer for 5 minutes at 37°C. Then, 20 L of cell extract
was mixed with 100 L of luciferase assay reagent, and the
light produced was measured for 30 seconds with a lumi-
Supplementary Table I (online only). Backgrounds of p
Sample Age Sex Diagnosis First opera
0a 72 M PAD F-Per
1 78 M PAD F-DP graft r
2 75 M PAD F-PBK redo
(spliced ve
3 70 M PAD F-Per
4 61 M PAD F-AT
5 73 F PAD Pop-PL
6 64 M PAD F-Per (splice
7 69 M PAD F-PBK (splic
vein)
8 75 F PAD F-Per
Summary 70.78  5.47 7:2 Spliced vein,
revision, 1
DM, Diabetes mellitus; F, female; F-AT, femoral-anterior tibial bypass; F-D
F-Per, femoral-peroneal bypass; GSV, great saphenous vein; HD, hemodialy
progressive systemic sclerosis; SHV, short saphenous vein.
aVein graft samples were collected for complementary DNA microarray ana
Supplementary Table II (online only). Instruments and
Product name
Instrument
Agilent 2100 Bioanalyzer A
GeneChip Fluidics Station 450 A
GeneChip Hybridization Oven 640 A
GeneChip Scanner 3000 7G A
High-speed refrigerated microcentrifuge T
NanoDrop 1000 Spectrophotometer T
PCR Thermal Cycler SP T
Analysis software
GeneChip Operating Software (GCOS) Anometer. oCell migration. Migration of transfected VSMCs was
stimated in a modified Boyden chamber. Cell migration
as examined in a 48-well microchemotaxis chamber with
olyvinylpyrrolidone-free polycarbonate membranes (Neuro
robe Inc, Gaithersburg,Md) with 8-mpores. Next, 32L
f DMEM containing 1% FBS was placed in the lower cham-
er. The membrane was positioned above the lower cham-
er, and 2.5  104 cells were suspended in 50 L of
MEM and added to the upper chamber. The Boyden
hamber was incubated at 37°C for 24 hours. After incu-
ation, the membrane was removed, and the cells on the
pper side of the membrane were scraped off. The cells on
he lower side of the membrane were stained with Diff-
uick (Sysmex, Hyogo, Japan) and were counted in six
andomly chosen fields under original magnification100.
Immunofluorescence analysis. Cells grown on glass
overslips were fixed in acetone for 5 minutes. The cells
ere permeabilized with 0.2% Triton X-100 in PBS for 2
inutes. After incubating the cell in 5% skim milk to block
onspecific binding, the cells were incubated with primary
ntibodies, includingmonoclonal mouse antihemagglutinin
BioVision Inc, Mountain View, Calif) and antiphospho-
yclic adenosine monophosphate (cAMP) response-element
inding protein (CREB; Ser133; Cell Signaling Technol-
ts supplying the vein graft samples
Months after
first operation
Sample
origin
Statin
therapy Comorbidity
6 GSV No
n 13 SSV No HD, DM
2 Arm vein No HD, DM
8 GSV No None
10 GSV No DM
6 GSV No PSS
) 7 GSV No None
8 LSV No DM
5 GSV Yes None
7.22  3.11 HD, 2; DM, 4;
PSS, 1
moral-dorsalis pedis bypass; F-PBK, femoral-popliteal below-knee bypass;
D, peripheral arterial disease; Pop-PL, popliteal-plantar artery bypass; PSS,
ysis software used for the gene chip analysis
Manufacturer Part. No.
Technologies, Santa Clara, Calif G2938B
trix, Santa Clara, Calif 00-0079
trix, Santa Clara, Calif 800-138
trix, Santa Clara, Calif 00-0210
Tech Biology Co, Tokyo, Japan MX-301
o Fisher Scientific, Fremont, Calif ND-1000
a Bio Inc, Shiga, Japan TP-400
trix, Santa Clara, Califatien
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Volume 57, Number 1 Nakanishi et al 193.e2primary antibodies were labeled a corresponding secondary
antibody, goat antirabbit immunoglobulin (Ig) G Alexa
Fluor 488 or goat antimouse immunoglobulin G Alexa
Fluor 546 (Molecular Probes, Eugene, Ore).
Paraffin-embedded 4-m sections of the human vein
graft or mouse femoral artery were deparaffinized and
rehydrated. The samples were permeabilized with 0.2%
Triton X-100 in phosphate-buffered saline for 2 minutes.
After incubating the samples in 5% skim milk to block
nonspecific binding, the samples were incubated at room
temperature with primary antibodies, either polyclonal rab-
bit anti-mitogen-activated protein kinase-activated protein
kinase 3 (MAPKAPK3; Novus Biologicals, Littleton, Colo)
and polyclonal rabbit anti-FHL5 (Novus Biologicals) for 1
hour at room temperature or monoclonal mouse anti–
-
smooth muscle actin (Thermo Fisher Scientific Inc, Fre-
mont, Calif) for 20 minutes. The corresponding secondary
antibodies were used for visualization: goat antirabbit IgG
Alexa Fluor 488 and goat antimouse IgG Alexa Fluor 546
(Molecular Probes).
Western blotting. Western blotting was performed to
analyze CREB expression using a phospho-specific anti-
body. After transfection, the cells were treated withNuclear
and Cytoplasmic Extraction Reagents (NE-PER; Pierce
Biotechnology, Rockford, Ill) to isolate cellular proteins.
Proteins in samples containing 20 g of protein were
separated on 5% to 20% polyacrylamide gradient gels and
transferred to iBlot nitrocellulose membranes (Invitrogen,
Carlsbad, Calif). The membranes were incubated with a
polyclonal antibody against phospho-CREB or total CREB
(polyclonal rabbit IgG, 1:1000; Cell Signaling Technol-
ogy) or actin (polyclonal rabbit IgG, 1:1000; Sigma-
Aldrich, St. Louis, Mo) at room temperature for 1 hour.
The membranes were washed and incubated with a 1:2000
dilution of anti-rabbit IgG horseradish peroxidase-
conjugated antibody (Amersham, Piscataway, NJ). Bound
antibodies were detected by enhanced chemiluminescence
(Amersham) and Hyperfilm-MP (Amersham).
Luciferase reporter gene assay. For pathway screen-
ing, baby-hamster-kidney (BHK) cell line 21 were cultured
in 24-well dishes and transiently cotransfected with each
candidate gene and several different reporter vectors that
contain a specific cis-acting DNA sequence (enhancer ele-
ment) and a sensitive reporter gene (Pathway Profiling
Luciferase System, Clontech Laboratories Inc, Mountain
View, Calif), as described in the manufacturer’s protocol.
These plasmids contain the luciferase reporter gene down-
stream of several copies of specific transcription factor-
binding sequences such as E2F, cyclic AMP response ele-
ment (CRE), serum response element (SRE), activator
protein 1 (AP-1), Myc, or nuclear factor (NF)-B. After 24
hours, luciferase activity was determined using the Lu-
ciferase Assay System (Promega).
Gel mobility shift analysis and competition and
antibody analysis. Nuclear extracts were prepared from
cultured VSMCs that overexpressed four-and-a-half LIM
domains 5 (FHL5) using NE-PER (Thermo scientific). A
gel retardation assay was performed using the Gel Shiftssay System (Promega) according to the manufacturer’s
nstructions; a double-stranded CREB-consensus oligode-
xynucleotide (Santa Cruz Biotechnology Inc, Santa Cruz,
alif) was used as the binding substrate. Antibody experi-
ents were performed by adding individual proteins and
he corresponding antibodies: anti-CREB antibody (Cell
ignaling, Beverly, MA), anti-FHL5 antibody (Cell Signal-
ng) or anti-hemagglutinin (HA) antibody (BioVision).
Polymerase chain reaction. Total RNA was extracted
rom samples using the RNeasy Plus Mini kit (Qiagen,
poorstraat, KJ Venlo, The Netherlands). Complementary
NA was synthesized using the Transcriptor High Fidelity
DNA Synthesis Kit (Roche Diagnostics, Mannheim, Ger-
any). To detect candidate gene and glyceraldehyde-3-phos-
hate dehydrogenase gene expression, the following oligom-
rs were used in the reverse transcription-polymerase chain
eaction:
APKAPK3: 5=-GGCGCACTGGACAGAAGTGTG-3=
and 5=-GACACCCAGGGAC-CACATGTC-3=;
HL5: 5=-ACTGCACAGCATCACTTCTT-3= and 5=-
CAAAATGTTATCCCACC-TGA-3=;
REB: 5=-TCTGCTCCCACCGTAACTCT-3= and 5=-
GAATGGTAGTACCCGGCTGA-3=; and
APDH: 5=-AGTCCATGCCATCACTGCCA-33= and
5=-CTTACTCCTTGGAGGCCATG-3=.
Relative messenger (m)RNA copy numbers of candidate
r target genes and -actin were quantified by real-time RT-
CR using TaqMan Gene Expression Assays (Mapkapk3,
m00628676; Fhl5, Mm00480451; Ccna2, Mm00438064;
os,Mm00487425;Rac1,Mm01201657;Bcl2,Mm00477631;
ctin , Mm00607939; CCNA2, Hs00996788; FOS,
s00170630; RAC1, Hs01902432; BCL2, Hs00608023;
CTIN , 99,999,903; Applied Biosystems, Foster City,
alif). The absolute number of mRNA copies was nor-
alized against -actin and standardized by a sample
tandard curve.
Protocols for elastica van Gieson staining.
1. Deparaffinization
2. Wash in water
3. Stain in Weigert Resorcin fuchsin at room temperature
for 40 minutes
4. Wash in water
5. Wash in 100% alcohol (twice)
6. Wash in water 2 minutes
7. Stain in iron hematoxylin 5 minutes
8. Wash in water
9. Differentiate in acid alcohol (twice)
0. Wash in water 2 minutes
1. Stain in van Gieson 7 minutes
2. Wash in water
3. Dehydrate, penetration, mounting
Protocols for elastica Masson trichrome staining.
1. Deparaffinization
2. Wash in water
3. Stain in Weigert Resorcin fuchsin at room temperaturefor 40 minutes
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5. Wash in 100% alcohol (twice)
6. Wash in water 2 minutes
7. Stain in iron hematoxylin 5 minutes
8. Wash in water
9. Differentiate in acid alcohol twice
10. Wash in water 5 minutes
11. Stain in Acid Red 26 disodium salt 20 minutes
12. 1% acetic acid solution (twice)
13. Differentiate in 2.5% phosphotungstic acid 5 minutes
14. 1% acetic acid solution (twice)
15. Stain in aniline blue 2 minutes
16. 1% acetic acid solution (twice)
17. Dehydrate, penetration, mounting
Plasmid constructs. Candidate genes were individu-
ally subcloned into a pGEM-T Easy Vector (Promega,
Madison, Wisc) in accordance with the manufacturer’s
instructions. The EcoRI insert from the pGEM-T Easy
Vector was ligated into the mammalian expression vector
pcDNA3.1 (Invitrogen, Carlsbad, Calif), which encodes
an HA tag, using Ligation high (TOYOBO, Osaka,
Japan). MAPKAPK3 and FHL5 were subcloned from
human vein graft sample cDNA using PCR and the
following primers:
MAPKAPK3 forward 5=-AGGTGCCACTAGAAGCGC-
CAG-3= and reverse 5=-AGGCTTAGGGTCAG-
GGTCCTC-3= and
FHL5 forward 5=-TCAAACCAAAATGACAACTGCTCA-3=
and reverse 5=-GTCTCCTAGATGTCAGTGTCC-3=.
Two types of CREB plasmids (CREB133 and KCREB)
were purchased from Clontech Laboratories (Mountain
View, Calif). Short hairpin (sh)-RNA plasmid of candidate
genes were purchased from Origene (Rockville, Md). The
sequence of the insert for the shRNA targeting MAPKAPK3
(sense) was 5=-AGTGGTCAGAAGTCTCTGAGGATGC-
CAAG-3=. The sequenceof the insert for the shRNAtargeting
FHL5 (sense) was 5=-CTGTCAATACTGCACAGCAT-
CACTTCTTG-3=. Knockdown efficacy of sh-MAPKAPK3
plasmids was 74.5%, and knockdown efficacy of sh-FHL5
plasmids was 71.4. (Data were not shown.)
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Volume 57, Number 1 Nakanishi et al 193.e4Supplementary Fig 1 (online only). The sample was div
(LCM).ided into whole vessels andmedia using laser microdissection
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Supplementary Fig 2 (online only). Screening for cell proliferation and migration-inducing gene. A, Effect of 13
candidate gene plasmids on vascular smooth muscle cell proliferation, as determined by a 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. Green fluorescent protein (GFP) plasmid
was transfected as control. n  6. B, Effect of six candidate gene plasmids on c-fos promoter activity in baby-hamster-
kidney cell line 21. GFP plasmid was transfected as control. n  6. *P .05 vs negative control. †P .05 vs positive
control. C, Effect of six candidate gene plasmids on baby-hamster-kidney cell line 21 proliferation, as determined by a
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. GFP plasmid
was transfected as a control. n  6. Negative control cells were incubated with 1% fetal bovine serum-containing
medium. Positive control cells were incubated with 15% fetal bovine serum-containing medium. D, Effect of six
candidate gene plasmids on vascular smoothmuscle cell migration, as determined by a modified Boyden chamber assay.
GFP plasmid was transfected as a control. n  11, *P .05 vs control. The error bars show the standard error of the
mean.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 1 Nakanishi et al 193.e6Supplementary Fig 3 (online only). Schematic diagram shows the signaling pathways of candidate genes and cyclic
adenosine monophosphate response-element binding protein (CREB). FHL5, four-and-a-half LIM domains 5;
MAPKAPK3, mitogen-activated protein kinase-activated protein kinase 3.P-CREB
Total-CREB
GFP plasmid + - - 
CREB133 plasmid
KCREB plasmid
-
-
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+
Supplementary Fig 4 (online only). Effect of short hairpin RNA
plasmids. Effect of a cyclic adenosine monophosphate response-
element binding protein (CREB) 133 plasmid or a KCREB plas-
mid on phosphorylation of the serine residue of cyclic adenosine
monophosphate response-element binding protein (p-CREB) in
vascular smooth muscle cells, as determined by Western blot. A
plasmid-encoding green fluorescent protein was transfected as a
control.
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January 2013193.e7 Nakanishi et alSupplementary Fig 5 (online only). Efficiency of gene transfer in mouse femoral artery. A, Representative pictures
of immunofluorescent stains for green fluorescent protein (GFP) and 4=,6-diamidino-2-phenylindole (DAPI) at 2 days
after in vivo transfection of microbubble-enhanced ultrasound method (original magnification, 1000). GFP trans-
fected cells (white arrows) B, Effect of in vivo transfection using microbubble-enhanced ultrasound method, as
determined by Western blot. A plasmid encoding the GFP was transfected.1.5
0.7
0.9
1.1
1.3
Fo
ld
in
cr
ea
se
(r
el
a
ve
to
0
w
ee
k)
0.5
0 1 2 3
weeks
Supplementary Fig 6 (online only). Expression of cyclic aden-
osine monophosphate response-element binding protein messen-
ger RNA at 0, 1, 2, or 3 weeks after mouse femoral artery wire
injury as assessed using reverse transcription-polymerase chain
reaction. n  6. The error bars show the standard error of the
mean.
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Volume 57, Number 1 Nakanishi et al 193.e8Supplementary Fig 7 (online only). Expression of two candidate genes in mouse femoral artery after wire injury.
Representative pictures of immunofluorescent stains in mouse femoral artery at two time points after wire injury.
MAPKAPK3 indicates staining with anti–mitogen-activated protein kinase-activated protein kinase 3 antibody (red),
FHL5 indicates staining with anti-four-and-a-half LIM domains 5 antibody (red), DAPI indicates nuclear staining
(blue) with 4’,6-diamidino-2-phenylindole. Merge indicates staining with both (original magnification, 1000).0.4
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Supplementary Fig 8 (online only). Lumen loss of mouse femoral artery after wire injury. A, Cross-sectional area
ratio of lumen/total artery area in injured artery transferred with green fluorescence protein (GFP) or cyclic adenosine
monophosphate response-element binding protein (KCREB). n 8. B, Cross-sectional area of lumen, internal elastic
lamina (IEL), and external elastic lamina (EEL) in injured arteries transfected with green fluorescence protein or
KCREB. n  8. The error bars show the standard error of the mean.
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Supplementary Fig 9 (online only). Lumen loss of mouse femoral artery after wire injury. A, Representative images
of scramble- or short hairpin (sh) RNA plasmid-transfected arteries stained with elastica van Gieson and elastica Masson
trichrome 3 weeks after vascular injury (bar 200 m). B,Cross-sectional area of lumen, internal elastic lamina (IEL),
external elastic lamina (EEL), intima, andmedia in injured arteries transfected with scramble-RNA or sh-RNA plasmids.
n  3. C, Cross-sectional area ratio of intima/media in injured artery transferred with scramble-RNA or sh-RNA
plasmids. n  3. The error bars show the standard error of the mean. FHL5, Four-and-a-half LIM domains 5;
MAPKAPK3, Mitogen-activated protein kinase-activated protein kinase 3 antibody.
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Supplementary Fig 10 (online only). Effect of short hairpin (sh)-RNA plasmids. A, Effect of sh-RNA plasmids on
vascular smooth muscle cell proliferation, as determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. Scramble plasmid was transfected as control. n  8. Negative control
cells were incubated with serum-free medium. Positive control cells were incubated with 50 ng/mL platelet-derived
growth factor–containing medium.B, Effect of short-hairpin RNA plasmids on vascular smooth muscle cell migration,
as determined by modified Boyden chamber assay. Scramble plasmid was transfected as control. n  4. Cells were
incubated with 50 ng/mL platelet-derived growth factor–containing medium. The error bars show the standard error
of the mean. FHL5, Four-and-a-half LIM domains 5; MAPKAPK3, Mitogen-activated protein kinase-activated
protein kinase 3 antibody.
